Want to see GB:TRUE full AI Analyst Report?
Top Page
Braveheart Investment
(LSE:TRUE)
Select Model
Select Model
Rating:40Underperform
Price Target:
2.00 p
▼(-38.46% Downside)
Action:Downgraded
Date:10/21/26
The score is driven down primarily by weak financial performance—especially persistent cash burn and deteriorated/volatile operating results—despite low reported debt. Technicals add further pressure as the stock trades below all major moving averages with negative momentum. Valuation is not a clear positive because the negative P/E reflects ongoing losses and no dividend yield data is available.
Positive Factors
Minimal Financial Leverage
Minimal debt reduces interest burden and refinancing exposure, giving Braveheart greater flexibility to manage its investment portfolio through difficult periods. Low leverage also leaves more room to deploy capital or support portfolio companies without the additional constraints created by substantial borrowings.
Negative Factors
Persistent Cash Burn
Persistent negative operating cash flow indicates that the core business has not funded itself through operations. Continued cash consumption can force reliance on external funding or existing resources, limiting the capital available for investments and increasing pressure on future financial decisions.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal Financial Leverage
Minimal debt reduces interest burden and refinancing exposure, giving Braveheart greater flexibility to manage its investment portfolio through difficult periods. Low leverage also leaves more room to deploy capital or support portfolio companies without the additional constraints created by substantial borrowings.
Read all positive factors
Braveheart Investment (TRUE) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£1.77M
Dividend Yield1.86%
Average Volume (3M)89.48K
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue GrowthN/A
EPS Growth68.42%
CountryUK
Employees3
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding78,473,490
10 Day Avg. Volume186,954
30 Day Avg. Volume89,480
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.55
Price to Sales (P/S)9.47
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Braveheart Investment Business Overview & Revenue Model
Company Description
Truetide plc is a private equity and venture capital firm specializing in loan, mezzanine, seed/startup, early venture, late stage, emerging growth, turnaround, distress situations, buyout and growth capital companies. It prefers to invest in mate...
Braveheart Investment Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 128.75K | 20.50K | 60.90K | 50.90K | 78.13K |
| Gross Profit | 60.32K | -274.18K | -366.56K | -505.24K | -558.01K |
| EBITDA | -421.87K | -565.91K | -811.88K | -788.22K | -695.49K |
| Net Income | -424.97K | -1.09M | -7.25M | 1.58M | 1.88M |
Balance Sheet | |||||
| Total Assets | 2.32M | 2.39M | 3.50M | 11.61M | 7.06M |
| Cash, Cash Equivalents and Short-Term Investments | 150.60K | 63.67K | 1.74M | 934.86K | 1.85M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 108.21K | 58.14K | 104.14K | 1.09M | 449.86K |
| Stockholders Equity | 2.22M | 2.33M | 3.40M | 10.52M | 6.63M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -541.01K | -736.12K | -768.19K | -1.28M |
| Operating Cash Flow | -536.99K | -541.01K | -736.12K | -768.19K | -1.27M |
| Investing Cash Flow | 344.32K | -1.14M | 1.54M | -1.08M | -1.40M |
| Financing Cash Flow | 279.59K | 0.00 | 0.00 | 930.36K | 2.42M |
Braveheart Investment Technical Analysis
Negative
3.25
Price Trends
3.07
Negative
3.17
Negative
2.71
Negative
Market Momentum
-0.24
Positive
1.95
Positive
19.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TRUE, the sentiment is Negative. The current price of 3.25 is above the 20-day moving average (MA) of 2.82, above the 50-day MA of 3.07, and above the 200-day MA of 2.71, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 1.95 is Positive, neither overbought nor oversold. The STOCH value of 19.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:TRUE.
Braveheart Investment Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
52 Neutral | £252.00K | -5.22 | -13.43% | ― | ― | ― | |
49 Neutral | £4.22M | 3.12 | 22.69% | 0.26% | ― | ― | |
46 Neutral | £1.67M | 2.75 | 22.42% | ― | ― | ― | |
42 Neutral | £1.79M | -1.24 | -43.66% | ― | ― | 83.53% | |
40 Underperform | £1.77M | -4.17 | -17.10% | 1.86% | ― | 68.42% |
* Financial Sector Average
GB:TRUE
Braveheart Investment
2.25
0.05
2.27%
GB:BLU
Blue Star Capital
3.50
-8.00
-69.57%
GB:GUN
Gunsynd
0.11
-0.06
-34.13%
GB:PRIM
Primorus Investments
3.40
-0.50
-12.82%
GB:VOX
Vertu Capital
0.18
0.00
0.00%
Braveheart Investment Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Truetide corrects Paraytec update as VosBio lung cancer project completes Phase 2
Positive
Oct 20, 2026
Truetide said an earlier regulatory announcement had been corrected to clarify that its Paraytec-VosBio lung cancer project is using simulated air samples, not human breath, and to remove premature technical claims about particle characterisation ...
Business Operations and StrategyProduct-Related Announcements
Truetide’s Paraytec Advances Breath-Based Lung Cancer Detection Programme
Positive
Oct 15, 2026
Truetide plc has reported that Paraytec Limited, its wholly owned investee, has successfully completed Phase 2 of a six-month development programme with VosBio Inc. to combine VosBio’s breath-collection technology with Paraytec’s CX300...
Business Operations and StrategyShareholder Meetings
Truetide Wins Shareholder Backing for New Investing Policy
Positive
Sep 7, 2026
Truetide plc has secured shareholder approval at a general meeting to amend its investing policy, with 83.79% of votes cast in favour of authorising the directors to implement the new strategy. The revised investing policy, which now takes immedia...
Business Operations and StrategyShareholder Meetings
Truetide Seeks Shareholder Backing for AI-Focused Expansion of Investing Strategy
Positive
Aug 21, 2026
Truetide plc has called a general meeting to seek shareholder approval for a significant expansion of its investing policy, adding a new artificial intelligence-focused strategy to its existing technology and knowledge-intensive investment framewo...
Shareholder Meetings
Truetide Wins AGM Backing but Faces Pushback on Share Allotment Powers
Neutral
Jul 24, 2026
Truetide plc reported that all resolutions at its annual general meeting on 24 July 2026 were passed, including the reappointment of MAH Chartered Accountants as auditors and the re-election of directors Vivian Hallam, Trevor Brown and Qu Li. Voti...
Business Operations and StrategyShareholder Meetings
Truetide Plans AI-Focused Long-Short Investment Strategy Shift
Positive
Jul 24, 2026
Truetide has outlined plans at its Annual General Meeting to amend its investing policy to adopt a balanced long-short, AI-focused investment strategy. The approach will target companies seen as beneficiaries of artificial intelligence while takin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.